<DOC>
	<DOCNO>NCT02293109</DOCNO>
	<brief_summary>This phase I trial study side effect best dose carfilzomib give together hyperfractionated ( hyper ) -cyclophosphamide , vincristine sulfate , doxorubicin hydrochloride , dexamethasone ( CVAD ) chemotherapy regimen treat patient newly diagnose acute lymphoblastic leukemia lymphoma . Carfilzomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cyclophosphamide , vincristine sulfate , doxorubicin hydrochloride , dexamethasone , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving carfilzomib combination chemotherapy may kill cancer cell .</brief_summary>
	<brief_title>Carfilzomib Hyper-CVAD Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Safety tolerability administer carfilzomib combination hyper-CVAD chemotherapy . II . Recommended dose carfilzomib combination hyper-CVAD chemotherapy future phase II trial . SECONDARY OBJECTIVES : I . Rate remission 2nd 4th cycle . II . Incidence minimal residual disease flow cytometry 4th cycle . OUTLINE : This dose escalation study carfilzomib . Patients receive carfilzomib intravenously ( IV ) 30 minute day 0 , 1 , 7 , 8 . Patients also receive hyper-CVAD comprising cyclophosphamide IV 2 hour every 12 hour 6 dos begin day 1 , vincristine sulfate IV day 4 11 , doxorubicin hydrochloride IV 2-24 hour day 4 , dexamethasone orally ( PO ) day 1-4 11-14 ( course 1 3 ) methotrexate IV 24 hour day 1 , cytarabine IV 2 hour every 12 hour 4 dos start day 2 , leucovorin calcium IV PO every 6 hour begin 36 hour start methotrexate infusion , methylprednisolone IV every 12 hour 6 dos begin day 1 ( course 2 4 ) . Patients cluster differentiation ( CD ) 20 positive disease also receive rituximab twice daily day 1 11 course 1 3 day 1 8 course 2 4 . Treatment repeat every 3-4 week 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 28 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Understand voluntarily sign informed consent form Able adhere study visit schedule protocol requirement Newly diagnose acute lymphoblastic leukemia/lymphoma Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ( 3 directly disease relate expect get good acute lymphoblastic leukemia/lymphoma [ ALL ] control ) Left ventricular ejection fraction ( LVEF ) &gt; 40 % Total bilirubin = &lt; 3 mg/dL Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 3.5 x upper limit normal Creatinine clearance ( CrCl ) &gt; = 45 mL/minute within 7 day prior enrollment either measure calculate use standard formula ( eg , Cockcroft Gault ) ; case creatinine clearance measure accurately , 24 hour urine use Disease free malignancy beside ALL time study Male subject must agree practice contraception Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 24 hour prior initiation study must agree ongoing pregnancy test practice contraception Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form Pregnant breast feeding female Active congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention Unstable angina myocardial infarction within 6 month prior enrollment , NYHA class III IV heart failure , uncontrolled angina , history severe coronary artery disease , severe uncontrolled ventricular arrhythmia , sick sinus syndrome , electrocardiographic evidence acute ischemia grade 3 conduction system abnormalities unless subject pacemaker Uncontrolled hypertension , uncontrolled pulmonary hypertension uncontrolled diabetes within 14 day prior enrollment Subjects pleural effusion require thoracentesis ascites require paracentesis within 14 day prior enrollment Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Use experimental drug therapy within 14 day baseline Known history allergy CaptisolÂ® Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) ; patient seropositive hepatitis B virus vaccine eligible Breakpoint cluster regionAbelson positive ( BCRABL + ) patient exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>